SCHEMBL27328037

SCHEMBL27328037

COc1cc2ncc(-c3nc(N[C@@H]4CCCNC4)ccc3C#N)n2nc1C1CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 11/20 0.53
▸ NRAS P01111 9/20 0.53
▸ IRAK4 Q9NWZ3 7/20 0.45
▸ CDK7 P50613 5/20 0.42
▸ CCNH P51946 5/20 0.42
▸ IRAK1 P51617 4/20 0.42
▸ PDGFRB P09619 3/20 0.42
▸ LCK P06239 2/20 0.42
▸ RET P07949 2/20 0.42
▸ MNAT1 P51948 2/20 0.41
▸ CHEK2 O96017 1/20 0.40
▸ ABL1 P00519 1/20 0.40
▸ PDGFRA P16234 1/20 0.40
▸ FLT4 P35916 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ DDR1 Q08345 1/20 0.40
▸ NTRK3 Q16288 1/20 0.40
▸ AURKB Q96GD4 1/20 0.40
▸ HTR2A P28223 1/20 0.40
▸ BLK P51451 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27332552 1.00 FLT3 (0.53) FLT3NRASIRAK4CDK7CCNH
SCHEMBL27327889 0.90 NRAS (0.53) FLT3NRASIRAK4CDK7CCNH
SCHEMBL27332436 0.90 NRAS (0.53) FLT3NRASIRAK4CDK7CCNH
SCHEMBL27329939 0.89 NRAS (0.49) FLT3NRASIRAK4CDK7CCNH
SCHEMBL27327393 0.89 NRAS (0.49) FLT3NRASIRAK4CDK7CCNH
SCHEMBL27327556 0.88 NRAS (0.49) FLT3NRASIRAK4CDK7CCNH
SCHEMBL27330027 0.88 NRAS (0.49) FLT3NRASIRAK4CDK7CCNH
SCHEMBL27332554 0.87 FLT3 (0.46) FLT3NRASIRAK4CDK7CCNH
SCHEMBL27328041 0.87 FLT3 (0.46) FLT3NRASIRAK4CDK7CCNH
SCHEMBL31739786 0.86 NRAS (0.51) FLT3NRASIRAK4CDK7CCNH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368648-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2025-12-04 — — US disclosed
WO-2023245123-A2 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2023-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368648-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF FLT3, IRAK1, IRAK2 FLT3 1/4885NRAS 371/4885IRAK4 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback